3.84
-0.06(-1.54%)
Currency In USD
| Previous Close | 3.9 |
| Open | 3.88 |
| Day High | 4.12 |
| Day Low | 3.84 |
| 52-Week High | 12.7 |
| 52-Week Low | 3.36 |
| Volume | 2,051 |
| Average Volume | 10,555 |
| Market Cap | 141.6M |
| PE | -1.86 |
| EPS | -2.07 |
| Moving Average 50 Days | 3.87 |
| Moving Average 200 Days | 4.87 |
| Change | -0.06 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $195.42 as of June 15, 2025 at a share price of $3.84. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $565.54 as of June 15, 2025 at a share price of $3.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
GlobeNewswire Inc.
Jun 11, 2025 8:00 PM GMT
Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosingData s
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
GlobeNewswire Inc.
Jun 10, 2025 5:00 AM GMT
Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR
Molecular Partners to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
May 19, 2025 5:00 AM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (